On June, 4 Analysts See $-0.30 EPS for Cellect Biotechnology Ltd. (APOP)

May 17, 2018 - By Rebecca Betts

On June, 4. Investors wait Cellect Biotechnology Ltd. (NASDAQ:APOP) to announce its quarterly earnings, Zacks reports. Analysts forecast $-0.30 EPS. That’s $0.26 down or 650.00 % from 2017’s earnings of $-0.04. Last quarter $-0.16 EPS was reported. Analysts predicts 87.50 % negative EPS growth this quarter. The stock increased 0.28% or $0.02 during the last trading session, hitting $7.13.Cellect Biotechnology Ltd. has volume of 17,074 shares. Since May 17, 2017 APOP has declined 42.02% and is downtrending. APOP underperformed by 53.57% the S&P 500.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel.The firm is valued at $46.41 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.Last it reported negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: